159 related articles for article (PubMed ID: 9002761)
1. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
[TBL] [Abstract][Full Text] [Related]
2. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
3. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
4. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
5. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
7. 111In-octreotide scintigraphy in pituitary adenomas.
Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
[TBL] [Abstract][Full Text] [Related]
8. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
10. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
11. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
12. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
13. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
[TBL] [Abstract][Full Text] [Related]
14. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
[TBL] [Abstract][Full Text] [Related]
15. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
[TBL] [Abstract][Full Text] [Related]
16. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.
van Royen EA; Verhoeff NP; Meylaerts SA; Miedema AR
J Nucl Med; 1996 Sep; 37(9):1449-51. PubMed ID: 8790190
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
[TBL] [Abstract][Full Text] [Related]
18. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
Acosta-Gómez MJ; Muros MA; Llamas-Elvira JM; Ramírez A; Ortega S; Sabatel G; Ramos C; de la Riva-Aguilar A
Br J Radiol; 2005 Feb; 78(926):110-5. PubMed ID: 15681321
[TBL] [Abstract][Full Text] [Related]
19. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic imaging of a TSH-producing pituitary adenoma associated with the "empty sella" by somatostatin and dopamine D2 receptor scintigraphy].
Berger F; Meyer G; Weiss M; Pfluger T; Horn K; Tatsch K; Hahn K
Nuklearmedizin; 2000; 39(1):42-5. PubMed ID: 10726258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
